Katherine M. Bell-McGuinn, MD, PhD

My clinical research is focused on new therapies for ovarian cancer. In particular, I am interested in the development of PARP inhibitor therapy for ovarian cancer and how best to combine this new class of agents with standard therapies.

Along with many of my colleagues at Memorial Sloan-Kettering, I am an active participant in the Gynecologic Oncology Group (GOG) — a national clinical research group that works to improve the care of women with gynecologic malignancies. I am a member of the GOG’s Phase I committee as well as the Experimental Medicine committee. Also with the GOG, I serve as the national principle investigator of phase I trials incorporating new biologic therapies into treatment for ovarian cancer.